Valo Therapeutics Acquires University of Helsinki´s technology that capitalizes on pre-existing immunity acquired via childhood vaccination programs to potentiate the efficacy of cancer treatment
Helsinki, Finland, 6th January 2022: Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the acquisition of intellectual property rights from the University of Helsinki, Finland, for the proprietary technology which utilises pre-existing immunity (PEI) against pathogens to enhance the therapeutic efficacy of ValoTx´s lead platform, PeptiCRAd.
